Nutriband (NASDAQ:NTRB) Releases Earnings Results

Nutriband (NASDAQ:NTRB) announced its quarterly earnings results on Friday. The company reported ($0.07) EPS for the quarter, FiscalAI reports. Nutriband had a negative net margin of 448.25% and a negative return on equity of 112.64%. The business had revenue of $0.44 million for the quarter.

Nutriband Stock Up 6.0%

NTRB stock traded up $0.34 during midday trading on Friday, hitting $5.97. The company’s stock had a trading volume of 91,075 shares, compared to its average volume of 15,611. The stock has a market cap of $72.60 million, a price-to-earnings ratio of -2.31 and a beta of 2.03. The stock’s 50-day moving average price is $3.41 and its 200 day moving average price is $3.65. Nutriband has a 1 year low of $2.80 and a 1 year high of $8.63.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On Nutriband

A hedge fund recently bought a new position in Nutriband stock. Cogent Private Wealth Inc. bought a new stake in Nutriband Inc. (NASDAQ:NTRB) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,014 shares of the company’s stock, valued at approximately $73,000. Cogent Private Wealth Inc. owned 0.13% of Nutriband at the end of the most recent reporting period. 19.70% of the stock is currently owned by institutional investors.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.